|

Does Voceryq Eliminate RRP Surgery? What FDA’s 7-of-26 Result Means

ByLife Choice Note

Short answer: On October 30, 2026, the U.S. FDA granted accelerated approval to Voceryq for reducing the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). It does not mean every patient will avoid surgery or that HPV infection is cured. The evidence came from a single-arm early-phase study of 32 adults. Among 26 participants who had required at least three surgeries during the baseline year, seven (27%) needed no surgery during the first year after treatment. FDA used reduced surgery frequency as an intermediate clinical endpoint and requires confirmatory trials to verify clinical benefit.

  • Decision date: October 30, 2026
  • Region: United States, FDA accelerated approval
  • Population: Adults with HPV-6- or HPV-11-associated recurrent respiratory papillomatosis
  • Indication: To reduce the frequency of surgical papilloma excisions
  • Not established by this decision: Use in children, treatment of other HPV diseases, a cure for RRP, or approval and reimbursement outside the United States

What is recurrent respiratory papillomatosis?

RRP is a rare chronic disease, usually caused by HPV types 6 or 11, in which wart-like papillomas repeatedly grow in the airways, particularly around the larynx and vocal cords. They can cause hoarseness, chronic cough and voice changes; severe disease can obstruct the airway and impair breathing. Surgery removes visible growths but does not necessarily clear virus from the tissue, so some people undergo repeated procedures over many years.

Voceryq is not the first FDA-approved product for RRP. FDA had already approved Papzimeos for adults with RRP in February 2026. The “first” in the October announcement refers specifically to the first plasmid DNA-based immunotherapy approved in the United States.

How does Voceryq work and how was it given?

Voceryq contains one plasmid encoding selected HPV-6 and HPV-11 proteins and another encoding the immune-response enhancer IL-12. After an intramuscular injection, a CELLECTRA device applies brief electrical pulses. This electroporation temporarily opens pores in cell membranes so the plasmid DNA can enter cells. The intended response is to stimulate T cells that recognize HPV-infected cells.

In the phase 1/2 RRP-001 study, 32 adults received four doses at weeks 0, 3, 6 and 9. A clinically indicated papilloma-removal procedure at study entry was counted in the baseline year. Investigators then compared surgical interventions during 52 weeks after dosing with each participant’s preceding year.

Why do “7 of 26” and “26 of 32” describe different results?

FDA highlighted a subgroup of 26 participants who had undergone at least three surgeries in the baseline year. Seven of those 26 (27%) required no surgical intervention during the first year after treatment. The published study examined all 32 participants and reported that 26 (81%) had fewer surgeries than during the previous year. “At least one fewer surgery” is not the same outcome as “no surgery.”

The trial had no randomized control group; each participant’s prior year served as the comparator. Natural fluctuation in RRP, clinician decisions about when to operate and differences in care can affect a before-and-after comparison. The 81% figure is not a cure rate, and the 27% no-surgery result should not be assumed for every adult with RRP.

What remains unproven under accelerated approval?

FDA determined that reduced surgery frequency is an intermediate endpoint reasonably likely to predict clinical benefit. The manufacturer must conduct post-approval trials to verify and describe that benefit, and continued approval can depend on the confirmatory evidence. Current data cannot establish long-term control of recurrence, durable improvement in voice or quality of life, prevention of malignant transformation, or whether repeat treatment will be needed.

The published trial’s primary endpoint was safety and tolerability rather than effectiveness. Treatment-related adverse events occurred in 13 of 32 participants (41%) and were low grade. FDA lists injection-site reactions, headache, fatigue, hypertension, nausea and dizziness among common reactions. Electroporation can also cause brief muscle contractions, temporary bleeding, vasovagal symptoms and injection-site pain.

Does this change care outside the United States?

Not automatically. This is a U.S. FDA decision. Authorization, supply and reimbursement in South Korea or other countries require separate regulatory review. People with RRP should not delay needed airway procedures or change treatment solely because of a foreign approval announcement. Papilloma location, airway risk, surgical history, HPV type and other conditions require individual assessment.

Important limitations

  • The evidence came from an open-label, single-arm phase 1/2 study of 32 adults, without a placebo or standard-care control group.
  • The no-surgery result highlighted by FDA applies to a 26-person subgroup with at least three baseline surgeries.
  • A before-and-after surgery count can be influenced by natural disease variation and decisions about when to operate.
  • Accelerated approval does not mean long-term clinical benefit has been confirmed; confirmatory evidence is required.
  • Adult U.S. data cannot automatically be generalized to children or patients in South Korea.

Primary sources

By: Life Choice Note — an independent personal health-information explainer based on official and primary sources.
Reviewed: October 31, 2026
Note: This article provides general information and does not diagnose RRP or direct the timing of surgery or other treatment. Discuss individual decisions with a qualified clinician.

Related guides